Gilead President Thinks Firm Is Safe From Pfizer/GSK HIV Joint Venture - For Now
This article was originally published in The Pink Sheet Daily
Executive Summary
Near term, Gilead’s Milligan doesn’t see “anything really competitive.”
You may also be interested in...
ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III
Phase II results presented at International AIDS Society meeting fuel speculation about co-formulations with other HIV drugs, including ViiV's Epzicom and Gilead's Truvada.
ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III
Phase II results presented at International AIDS Society meeting fuel speculation about co-formulations with other HIV drugs, including ViiV's Epzicom and Gilead's Truvada.
Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
The four-drug combination pill for HIV has significant sales potential, and will be a mainstay for Gilead to protect its leadership in the market, but with two novel components there is still much work to be done.